Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.1952W HIGH $33.13
Volume
3.54 M
Value Traded
137.22 M
Short % Float
11%
Days to Cover
2.5
+5.35%Week
+1.5%1 Month
+97.77%3 Month
+49.35%6 Month
-42.41%5 Year
-42.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.79 B
EPS (TTM)
0.37
P/E Ratio
83.63
Ent. Value
8.39 B
Total Shares
282.60 M
Float Shares
126.34 M
Insiders
55.29%
Institutions
50.41%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CAI Catalyst Timeline
Dated clinical, regulatory and corporate events for Caris Life Sciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Caris Life Sciences, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
▲Product LaunchPost-Market
Commercial launch of Caris Detect multi-cancer early detection blood test
multi-cancer early detectionsource ↗
Past FDA Catalysts and PDUFA Decisions
How CAI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Caris Life Sciences, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CAI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| pembrolizumab | 2026-05-11 | In a study of 3,981 'TMB reliant' patients treated with pembrolizumab, those with WES TMB-High and panel TMB-Low had a median overall survival of approximately five months longer compared to those with WES TMB-Low and panel TMB-High (p < 0.05).Read More | Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene PanelsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Denton John RusselOfficer (See Remarks) | Sell | -7,500 174,855 held | $31.82 | 09/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CAI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.9 % (-10 %) | 50.02 M | 2.81 M |
CAI Institutional Ownership Trends
CAI Short Interest
Shares sold short, counted twice a month.
11%
Short % of Float
of tradable shares sold short
13.9M
Shares Sold Short
+4.2% vs prior count
2.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
5.6M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CAI ranks across every disease it competes in
Competitive Position is a premium feature
See how CAI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCAI News
CAI▲ +2%today
Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
Caris Life Sciences has launched a new commercial for its multi-cancer early detection test, Caris Detect, featuring golfer Jordan Spieth. The campaign emphasizes the application of artificial intelligence in identifying early-stage cancer, paralleling its use in sports performance analysis. The test utilizes advanced molecular sequencing techniques to enhance cancer detection capabilities.
Read more →CAICaris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Caris Life Sciences has announced that it will report its third quarter 2026 financial results on November 4, 2026. A live webcast will be held at 3:30 p.m. CT to discuss these results. The company is recognized for its innovative approaches in precision medicine, utilizing advanced technologies in molecular profiling.
Read more →CAICaris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
Caris Life Sciences will present eight studies at the ESMO Congress 2026, highlighting the role of AI and multi-omics in precision oncology. The research covers various cancer types, including breast and lung cancer, and emphasizes the integration of AI with clinical data to improve treatment predictions and patient outcomes. This presentation underscores the company's commitment to advancing precision medicine.
Read more →CAICaris Life Sciences Unveils the Next Evolution of Liquid Biopsy with Enhanced Caris Assure
Caris Life Sciences has launched the enhanced Caris Assure, a liquid biopsy platform that integrates Whole Exome Sequencing, Whole Transcriptome Sequencing, and whole-blood analysis. This new assay aims to provide a more comprehensive molecular profile from a single blood draw, improving precision oncology decisions. The platform enhances tumor fraction validation and offers a refined reporting experience for physicians.
Read more →CAICaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
Caris Life Sciences has launched a national campaign featuring Kevin Costner to promote its multi-cancer early detection blood test, Caris Detect. The campaign emphasizes the importance of early cancer detection, which can lead to better treatment options and outcomes. Caris Detect utilizes advanced molecular science and AI to identify cancer signals in the bloodstream, aiming to empower individuals in their healthcare decisions.
Read more →CAICaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Caris Life Sciences will present seven studies at the IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea. The research focuses on comprehensive molecular profiling and AI-driven analyses to enhance understanding of lung cancer biology and treatment strategies. Key presentations will cover topics such as immunotherapy biomarkers and transcriptomic subtypes in mesothelioma.
Read more →CAICaris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Caris Life Sciences has published a study in npj Precision Oncology demonstrating that its AI-driven therapy selection can significantly improve survival rates in pancreatic cancer patients. The study found that patients treated with FOLFIRINOX based on AI predictions had a median overall survival of 16 months compared to 9.9 months with gemcitabine. This approach aims to enhance personalized treatment and reduce toxicity for patients.
Read more →CAI▲ +21.6%on this news· ran to +41% by day 3
Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer
Caris Life Sciences announced a study demonstrating a multimodal AI model that predicts late distant recurrence risk in HR+ early breast cancer. Conducted in collaboration with ECOG-ACRIN and NRG Oncology, the study utilized data from over 6,500 patients. The findings suggest this AI approach could enhance individualized treatment decisions regarding extended endocrine therapy.
Read more →CAI▲ +21.6%on this news· ran to +41% by day 3shared move
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences reported a strong second quarter for 2026, with total revenue reaching $263.7 million, a 45% increase from the previous year. The company raised its revenue guidance for the year to between $1.03 and $1.04 billion, reflecting a growth of 27% to 28%. Key product launches, including Caris Detect, contributed to this growth, while the company also reported a net loss of $0.6 million amidst rising operating expenses.
Read more →CAI▼ -5.6%on this news
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
Caris Life Sciences has announced that it will report its financial results for the second quarter of 2026 on August 5, 2026. The company will host a live webcast to discuss these results at 3:30 p.m. CT. Caris is known for its innovative solutions in precision medicine, utilizing advanced technologies for healthcare transformation.
Read more →CAICaris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
Caris Life Sciences has announced the launch of in-house PTEN immunohistochemistry (IHC) testing following FDA approval of a biomarker-guided therapy for PTEN-deficient metastatic prostate cancer. This advancement allows oncologists to better identify eligible patients for personalized treatment, marking a significant step forward in precision oncology. The new testing capability is expected to enhance treatment decisions and improve patient outcomes.
Read more →CAI▲ +5.2%on this newsshared move
Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
Caris Life Sciences has launched Caris Detect, a multi-cancer early detection blood test that utilizes ultra-deep Whole Genome and Whole Transcriptome sequencing combined with AI. This innovative test aims to identify cancer signals at earlier stages, improving treatment outcomes. The launch is supported by data from the Caris Detect ACHIEVE 1 study, demonstrating its effectiveness across multiple cancer types.
Read more →CAICaris Life Sciences Announces Dual Listing on NYSE Texas
Caris Life Sciences announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. This move aims to enhance its visibility in the public markets while maintaining its primary listing on NASDAQ. The company's CEO highlighted the significance of this milestone in reflecting their growth and commitment to innovation in precision medicine.
Read more →CAICaris Life Sciences Announces Share Repurchase Program
Caris Life Sciences has announced a share repurchase program authorized by its Board of Directors, allowing the company to buy back up to $100 million of its common stock. The repurchases can occur through various methods, including open market purchases, and will depend on market conditions and the company's financial health. The program offers flexibility but does not obligate the company to repurchase a specific number of shares.
Read more →CAICaris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
Caris Life Sciences has launched the "Behind the Diagnosis" campaign, showcasing patient stories transformed by its genomic testing. The inaugural story features Erika Rios, whose misdiagnosis of stage 4 metastatic breast cancer was corrected to Hodgkin lymphoma through Caris' AI-powered GPSai model. This correction led to a more effective treatment plan, emphasizing the importance of accurate molecular profiling in oncology.
Read more →CAICaris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek
Caris Life Sciences has published a study showcasing the Caris Lookback Program, which identifies patients eligible for newly approved targeted therapies based on their previous molecular profiles. The program continuously monitors FDA approvals and therapeutic guidelines, allowing for proactive notifications to oncologists. This approach enhances the clinical utility of comprehensive testing and supports ongoing advancements in precision oncology.
Read more →CAICaris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Caris Life Sciences published a study demonstrating that Whole Exome Sequencing (WES) offers a more accurate measurement of tumor mutational burden (TMB) than targeted gene panels. The research indicates that WES can lead to better patient outcomes by correctly identifying those eligible for pembrolizumab immunotherapy. The findings emphasize the necessity of using WES for precise therapy selection in cancer treatment.
Read more →CAI▼ -18.6%on this newsshared move
Caris Life Sciences Reports First Quarter 2026 Financial Results
Caris Life Sciences reported a strong financial performance for Q1 2026, with total revenue reaching $216.2 million, a 79% increase from the previous year. The growth was primarily driven by an 85% surge in molecular profiling services. The company also noted a significant reduction in net loss and reaffirmed its revenue guidance for the full year, projecting growth between 23% and 26%. CEO David Dean Halbert highlighted the demand for their platform and the positive data from their Achieve 1 study.
Read more →CAI▼ -18.6%on this newsshared move
Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization
Caris Life Sciences has submitted an application to the New York State Department of Health for authorization to perform its blood-based molecular profiling test, Caris Assure. This test analyzes genetic information to support comprehensive biomarker analysis. The application initiates a formal review process, and until authorized, the test cannot be used on New York specimens.
Read more →CAICaris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis
Caris Life Sciences has launched Caris MI Clarity, an AI-powered test that predicts both early and late distant recurrence risk for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer. This innovative test provides results within three business days, significantly faster than traditional methods. It aims to enhance treatment personalization by integrating pathology and clinical data, addressing the evolving nature of recurrence risk over time.
Read more →About Caris Life Sciences, Inc.
Headquarters750 W JOHN CARPENTER FREEWAY, IRVING, TX, 75039
BIOPHARMAWATCH ELITE PLUS
Trade the next CAI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime